Efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe

被引:12
|
作者
Zhu, Yijun [1 ,2 ]
Pan, Jing [1 ]
Zhang, Shunli [1 ]
Liu, Zhenren [1 ]
Ye, Deyong [2 ]
Zhou, Weicheng [1 ]
机构
[1] State Inst Pharmaceut Ind, Shanghai Key Lab Antiinfect, State Key Lab New Drug & Pharmaceut Proc, Shanghai, Peoples R China
[2] Fudan Univ, Sch Pharm, Shanghai, Peoples R China
关键词
(S)-4-phenyl-2-oxazolidinone; ezetimibe; NaBH4/I-2; process; stereoselective; CHOLESTEROL ABSORPTION INHIBITORS; PRIMARY HYPERCHOLESTEROLEMIA; ENANTIOSELECTIVE REDUCTION; KETONES; NABH4/I-2;
D O I
10.1080/00397911.2016.1221969
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
An efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe through chiral Evans auxiliary (S)-4-phenyl-2-oxazolidinone is described. The key steps in this process are the condensation of (S)-3-(5-(4-fluorophenyl)-5,5-dimethoxypentanoyl)-4-phenyloxazolidin-2-one and N-(4-((tert-butyldimethylsilyl)oxy)benzylidene)-4-fluoroaniline, and the stereoselective reduction of ezetimibe-ketone with NaBH4/I-2, which is first applied in the synthesis of ezetimibe. The process is concise, mild, easy to operate, and highly stereoselective (99.6% of de value of ezetimibe). In addition, three diastereomers of ezetimibe are synthesized and served as the references in quality control of the product. [GRAPHICS] .
引用
收藏
页码:1687 / 1693
页数:7
相关论文
共 50 条
  • [21] Drug-Induced Liver Injury Associated with Ezetimibe Therapy
    Qiang Liu
    Hillel Tobias
    Lydia M. Petrovic
    Digestive Diseases and Sciences, 2007, 52 : 602 - 605
  • [22] Serious drug-induced liver disease secondary to ezetimibe
    José Castellote
    Javier Ariza
    Rosa Rota
    Anna Girbau
    Xavier Xiol
    World Journal of Gastroenterology, 2008, (32) : 5098 - 5099
  • [23] Drug-induced liver injury associated with ezetimibe therapy
    Liu, Qiang
    Tobias, Hillel
    Petrovic, Lydia M.
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (02) : 602 - 605
  • [24] Pharmacokinetic drug evaluation of ezetimibe plus simvastatin for the treatment of hypercholesterolemia
    Bove, Marilisa
    Fogacci, Federica
    Cicero, Arrigo F. G.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (10) : 1099 - 1104
  • [25] A convenient synthesis of ezetimibe analogs as cholesterol absorption inhibitors
    Ji, Jian Feng
    Zhang, Hui Bin
    Huang, Wen Long
    Qian, Hai
    Zhou, Jin Pei
    CHINESE CHEMICAL LETTERS, 2010, 21 (01) : 67 - 69
  • [26] Synthesis of deuterium labeled ezetimibe and its glucuronide conjugate
    Lei Tian
    Jian Li
    Mei He
    Journal of Radioanalytical and Nuclear Chemistry, 2021, 329 : 695 - 700
  • [27] Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product
    Luo, Zhiqiang
    Deng, Zhongqing
    Liu, Yang
    Wang, Guopeng
    Yang, Wenning
    Hou, Chengbo
    Tang, Minming
    Yang, Ruirui
    Zhou, Huaming
    TALANTA, 2015, 139 : 67 - 74
  • [28] Synthesis of deuterium labeled ezetimibe and its glucuronide conjugate
    Tian, Lei
    Li, Jian
    He, Mei
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2021, 329 (02) : 695 - 700
  • [29] Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol
    Gotto, Antonio M., Jr.
    Farmer, John A.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (12): : 664 - 672
  • [30] Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe
    Derks, Michael
    Abt, Markus
    Phelan, Mary
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (06) : 825 - 833